Advertisement
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY

Major Role of Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) in the Oxidative Metabolism of Celecoxib, a Novel Cyclooxygenase-II Inhibitor

Cuyue Tang, Magang Shou, Qin Mei, Thomas H. Rushmore and A. David Rodrigues
Journal of Pharmacology and Experimental Therapeutics May 2000, 293 (2) 453-459;

Abstract

In vitro studies were conducted to identify the cytochromes P450 (CYP) involved in the oxidative metabolism of celecoxib. The hydroxylation of celecoxib conformed to monophasic Michaelis-Menten kinetics (mean ± S.D., n = 4 livers,Km = 3.8 ± 0.95 μM,Vmax = 0.70 ± 0.45 nmol/min/mg protein) in the presence of human liver microsomes, although substrate inhibition was significant at higher celecoxib concentrations. The treatment of a panel of human liver microsomal samples (n = 16 subjects) with antibodies against CYP2C9 and CYP3A4 inhibited the formation of hydroxy celecoxib by 72 to 92% and 0 to 27%, respectively. The presence of both antibodies in the incubation suppressed the activity by 90 to 94%. In addition, the formation of hydroxy celecoxib significantly correlated with CYP2C9-selective tolbutamide methyl hydroxylation (r = 0.92, P < .001) and CYP3A-selective testosterone 6β-hydroxylation (r= 0.55, P < .02). In contrast, correlation with activities selective for other forms of CYP was weak (r ≤ 0.46). Chemical inhibition studies showed that ketoconazole (selective for CYP3A4) and sulfaphenazole (selective for CYP2C9) inhibited the formation of hydroxy celecoxib in a concentration-dependent manner, whereas potent inhibitors selective for other forms of CYP did not show any significant effect over a range of 1 to 10 μM. In agreement, cDNA-expressed CYP2C9 catalyzed the formation of hydroxy celecoxib with an apparentKm value (μM) and aVmax value (pmol/min/pmol recombinant CYP) of 5.9 and 21.7, whereas a higher Km value (18.2) and a lower Vmax value (1.42) were obtained with rCYP3A4. It is concluded that methyl hydroxylation of celecoxib is primarily catalyzed by human liver microsomal CYP2C9, although CYP3A4 also plays a role.

Cyclooxygenase (COX) is an enzyme that catalyzes the first two steps in the biosynthesis of prostaglandins from arachidonic acid (Riendeau et al., 1997; Vane et al., 1998). Although it was long held that COX was a single enzyme present in most cells (Graul et al., 1997), more recent data have pointed to the existence of two forms (Vane et al., 1998). COX-I is the major form located in healthy tissues, and it plays a role in thrombogenesis and homeostasis of the gastrointestinal tract and kidneys (Smith and DeWitt, 1996). In contrast, COX-II is normally undetectable in most tissues and is inducible by cytokines, endotoxins, and mitogens. It has been associated with the elevated production of prostaglandins observed during inflammation, pain, and pyretic responses (Donnelly and Hawkey, 1997; Jouzeau et al., 1997; Lane, 1997;Lipsky and Isakson, 1997). Both forms of COX metabolize arachidonic acid via a similar mechanism, but they have different substrate specificities. COX-II accepts a wider range of substrates than COX-I (Battistini et al.,1994).

Most nonsteroidal anti-inflammatory drugs (NSAIDs) currently in use, such as indomethacin, ibuprofen, and diclofenac, inhibit both COX-I and COX-II with little or no selectivity for either form of the enzyme (Battistini et al., 1994; O'Neill et al., 1994). It is believed that NSAID-induced gastrointestinal damage and platelet and renal dysfunction result from the inhibition of COX-I, whereas the therapeutic benefit results from the inhibition of COX-II expressed at the sites of inflammation (Simon et al., 1998). Therefore, the identification and characterization of two isoforms of cyclooxygenase have stimulated tremendous efforts to develop potent and selective COX-II inhibitors (Penning et al., 1997; Simon et al., 1998). Celecoxib [Celebrex; SC-58635; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonimide] is one example of a COX-II-selective agent (Fig.1), and it has been approved by the Food and Drug Administration for the treatment of osteoarthritis and rheumatoid arthritis (Penning et al., 1997; Simon et al., 1998).

Figure 1
Figure 1

Proposed major celecoxib oxidative pathway.

Celecoxib is well absorbed and is extensively metabolized in humans, with less than 3% of the dose excreted unchanged in urine and feces (Karim et al., 1997). The major route of metabolism appears to be methyl hydroxylation, with further oxidation to the corresponding carboxylic acid (Fig. 1). Although CYP2C9 has been implicated (Karim et al., 1997), a complete CYP reaction phenotype of celecoxib remains to be determined. Toward this end, the purpose of the present study was to define the NADPH-dependent metabolism of celecoxib in human liver microsomes and to determine which CYP protein or proteins were involved, using a combination of four approaches: 1) immunoinhibition, 2) chemical inhibition, 3) correlation analysis, and 4) cDNA-expressed human CYP proteins.

Materials and Methods

Chemicals and Biologicals.

Ketoconazole (KTZ) and sulfaphenazole (SLF) were purchased from Research Biochemicals Inc. (Natick, MA). Quinidine (QND) and diclofenac were obtained from Sigma Chemical Co. (St. Louis, MO). The in-house preparations of CYP2C9, CYP3A4, CYP1A2, CYP2C19, CYP2D6, and CYP2E1 were used for kinetic studies or the determination of reaction rates. The procedures for their preparation have been described elsewhere (Mei et al., 1999). Individual and pooled human liver microsomal samples were purchased from the Gentest Corporation (Woburn, MA) and The International Institute for the Advancement of Medicine (Exton, PA). A bank of fully characterized human liver microsomes (n = 16 different organ donors) was purchased from Xenotech LLC (Kansas City, KS). Mouse ascites containing monoclonal antibodies (mAbs) raised against CYP2C9 (mAb2C9a) and CYP3A4 (mAb3A4a) were prepared in-house. The antibodies have been characterized with respect to their CYP selectivity (Mei et al., 1999). Other reagents were purchased from commercial sources in the best available grade.

Incubation of Celecoxib with Native Human Liver Microsomes.

In vitro incubations were carried out at 37°C in a Fisher shaking water bath with 13- × 100-mm borosilicate glass disposable culture tubes. The incubation mixture (final volume of 0.5 ml) consisted of 0.1 M potassium phosphate buffer, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 1.0 mM NADP+, 10 mM d-glucose-6-phosphate, 2.0 U/ml d-glucose-6-phosphate dehydrogenase (Sigma Type VII, from baker's yeast), 0.10 to 0.20 mg/ml microsomal protein, and 0.5 to 50 μM celecoxib dissolved in acetonitrile (0.3% v/v final concentration). The reaction was started by the addition of the NADPH-generating system after a 5-min preincubation and was terminated with 2 ml of acetonitrile. The internal standard, diclofenac (50 μl of a 100 μM stock), was added to the sample before centrifugation. The supernatant was transferred to a clean tube and evaporated to dryness (SpeedVac; Savant Instruments, Inc., Holbrook, NY). In each case, the residue was reconstituted in 150 μl of aqueous solution of acetonitrile (30%) for HPLC analysis. Under these conditions, the rate of hydroxy celecoxib formation was linear with respect to protein concentration and time of incubation.

Measurement of CYP Form-Selective Activities.

Microsomal samples (Xenotech, LLC) were prepared for incubation and analysis as described earlier. The rate of celecoxib (15 μM) hydroxylation was correlated with the various CYP monooxygenase activities (data provided by Xenotech, LLC), including 7-ethoxyresorufin O-deethylase (CYP1A2), coumarin 7-hydroxylase (CYP2A6), taxol 6-hydroxylase (CYP2C8), tolbutamide methyl-hydroxylase (CYP2C9), (S)-mephenytoin 4′-hydroxylase (CYP2C19), chlorzoxazone 6-hydroxylase (CYP2E1), bufuralol 1′-hydroxylase (CYP2D6), and testosterone 6β-hydroxylase (CYP3A4/5). Correlation coefficients (r) were determined graphically and subjected to the Student's t test (Rodrigues et al., 1996).

CYP-Selective Inhibitors.

Inhibition studies with CYP form-selective chemical inhibitors were carried out at a final celecoxib concentration of 5 μM (∼Km). Microsomal preparations from the livers of three different subjects were used. SLF (0.1–10 μM, CYP2C9), QND (0.1–10 μM, CYP2D6), and KTZ (0.1–10 μM, CYP3A4) were dissolved in 50% (v/v) acetonitrile as stock solutions. The inhibitors were individually incubated with each microsomal sample (0.10 mg protein/ml) and substrate for 20 min. Control incubations contained the same concentration of acetonitrile but no inhibitor (≤1% v/v final concentration). Inhibitor concentrations were chosen on the basis of established Ki values (Bourrie et al., 1995; Newton et al., 1995; Rodrigues et al., 1996) to ensure maximal inhibition (>80%) of each CYP form ([I]/Ki ≥ 10; [S] ≤Km).

Incubations with cDNA-Expressed Human CYP Microsomes.

Incubations of celecoxib with various individual recombinant CYP (rCYP) proteins were carried out as described for liver microsomes, except that the enzyme concentration was 5 or 25 nM.

For all CYP proteins tested, the reaction rates (picomoles per minute per picomole of CYP) were normalized (picomoles per minute per picomole · picomoles of CYP per milligram) with respect to the corresponding nominal (mean) specific content of each CYP in native human liver microsomes (data provided by Gentest Corp.). The normalized rates (picomoles per minute per milligram) were then added, and the normalized rate for each CYP was expressed as the percentage of the total normalized rate (Rodrigues, 1999). The apparentKm andVmax values were determined using in-house preparations of rCYP2C9 and rCYP3A4 at final enzyme concentrations of 10 and 25 nM, respectively.

Immunoinhibition Studies.

Mouse ascites, fluid containing the respective antibodies, were diluted with potassium phosphate buffer (1:1, 1:2, 1:4, 1:8, 1:16, 1:32, and 1:64 dilutions). An aliquot (20 μl) of each diluted ascites solution was incubated with 50 μg human liver microsome protein (50 μl) at room temperature for 20 min before the addition of MgCl2, EDTA, celecoxib, and phosphate buffer. The inhibitory potency of each antibody preparation was confirmed after coincubation with the appropriate rCYP. In a second experiment, a panel of human liver microsomes (n = 16 livers) was preincubated with an aliquot (20 μl) of undiluted (for anti-CYP2C9 mAb) or diluted (1:32, for anti-CYP3A4 mAb) mouse ascites to examine the effect of antibody treatment on the correlation of hydroxy celecoxib formation with the corresponding CYP form-selective activity. The final concentrations of celecoxib and human liver microsomes were 15 μM and 0.1 mg/ml, respectively.

Kinetic Analysis.

Estimates of apparentKm andVmax values were obtained by fitting the untransformed data to a one- or two-enzyme model (GraFit 3;Leatherbarrow, 1992). After initial kinetic parameter estimates were obtained, the data were also analyzed by linear transformation (Eadie-Hofstee plot) to confirm a singleKm model.

HPLC-UV Analysis.

Celecoxib and its metabolites were separated on a reversed phase C18 column (4.6 × 150 mm, 5 μm, Betasil; Keystone, Bellefonte, PA) using a Shimadzu LC-10AS HPLC system. The mobile phase consisted of 0.05% aqueous phosphoric acid (solvent A) and acetonitrile/H2O (90:10) in 0.05% phosphoric acid (solvent B) and was delivered at a constant flow rate of 1.0 ml/min. The initial mobile phase consisted of 30% of solvent B, which increased linearly to 80% over 13 min, and the elution of celecoxib and hydroxy celecoxib was monitored by UV detection (254 nm). Hydroxy celecoxib, the internal standard (diclofenac), and celecoxib eluted at 10.2, 13.5, and 14.8 min, respectively, under these conditions. Due to the unavailability of hydroxy celecoxib standard, its quantification was achieved by using the calibration curve for carboxy celecoxib (assuming a similar extinction coefficient). Calibration curves were prepared by adding known quantities of carboxy celecoxib and the internal standard to control incubation mixtures. The lower limit of quantification in this study was 25 pmol/ml. The assay was linear over a carboxy celecoxib concentration range of 25 pmol/ml to 10 nmol/ml.

Liquid Chromatography (LC)-Mass Spectrometry (MS) Analysis.

HPLC separation was carried out on an HP-1050 gradient system (Hewlett-Packard, Palo Alto, CA) using a Betasil C18 column (2 × 150 mm, 5 μm). The mobile phase consisted of 0.2% aqueous acetic acid with pH adjusted to 7.6 with NH4OH (solvent A) and acetonitrile (solvent B) and was delivered at a constant flow rate of 0.2 ml/min. The initial mobile phase consisted of 10% of solvent B, which was held for 3 min and then linearly increased to 80% over 35 min.

The column eluant was coupled directly to a Finnigan MAT LCQ ion trap mass spectrometer. Mass spectral analyses were performed using electrospray ionization in the negative mode. The electrospray ionizing voltage was set at 4.5 kV, and the heated capillary temperature was maintained at 230°C for all analyses. Collision energy value was set at 25% for the MS/MS experiments. Under these conditions, hydroxy celecoxib yielded an [M-H]− ion atm/z 396 on MS analysis. MS/MS of this parent ion produced intense fragment ions at m/z332(M-H-SO2)−,m/z 302 (M-H-SO2-HCOH)−, andm/z 282 (M-H-SO2-HCOH-HF)−.

Results

Metabolism of Celecoxib.

A typical UV chromatogram of the extract after incubation of celecoxib with NADPH-fortified human liver microsomes is shown in Fig. 2. After incubation, one major metabolite (retention time, 10.2 min) was detected and identified (LC-MS/MS) as hydroxy celecoxib (Fig. 1). No carboxy celecoxib was detected, although minor amounts of the corresponding aldehyde were detected by LC-MS (data not shown).

Figure 2
Figure 2

Representative UV chromatogram after incubation of celecoxib with native human liver microsomes. 1, hydroxy celecoxib (10.2 min). 2, diclofenac (internal standard, 13.5 min). 3, celecoxib (14.8 min).

Overall, the formation of methyl hydroxy celecoxib conformed to saturable kinetics, and a representative Michaelis-Menten plot (pool ofn = 10 different livers) is presented in Fig.3. A slight but significant decrease in hydroxy celecoxib formation was observed at higher celecoxib concentrations. Similar results were obtained with microsomal preparations of three individual livers (data not shown). Therefore, only the data acquired at substrate concentrations of ≤20 μM were fitted to the simple Michaelis-Menten equation for the determination of kinetic parameters (Table 1). Eadie-Hofstee plots of those data indicated that hydroxylation of celecoxib in human liver microsomes exhibited monophasic enzyme kinetics over the substrate concentration range of 1 to 20 μM (Fig.3, inset).

Figure 3
Figure 3

Rate of formation of hydroxy celecoxib by a pool of human liver microsomes (HHM-0259). Inset, Eadie-Hofstee plot.

View this table:
Table 1

Apparent kinetic parameters for the formation of hydroxy celecoxib in the presence of human liver microsomes

Immunoinhibition of Hydroxy Celecoxib Formation.

The mAb against human CYP2C9 significantly inhibited the formation of hydroxy celecoxib in human liver microsomes, yielding up to >85% inhibition in a concentration-dependent manner (Fig.4A). The mAbs against human CYP3A4 suppressed hydroxy celecoxib formation by ∼10% at low concentrations, and its inhibitory effect diminished as the concentration of ascites increased. When the volume of ascites reached >5 μl, a small but significant rise in the rate of hydroxy celecoxib formation was observed (Fig. 4B). To avoid stimulation of celecoxib hydroxylase activity, therefore, the ascites fluid containing anti-CYP3A4 was diluted (1:32) in subsequent experiments. The presence of both antibodies in the incubation system almost completely inhibited the formation of hydroxy celecoxib (90–95% inhibition) as shown in Fig. 4C. The treatment of a panel of human liver microsomal samples (n = 16 subjects) with antibodies against CYP2C9 and CYP3A4 inhibited the formation of hydroxy celecoxib by 72 to 92% and 0 to 27%, respectively (Fig. 5).

Figure 4
Figure 4

Concentration-dependent inhibition of hydroxy celecoxib formation in human liver microsomes by anti-CYP2C9 and anti-CYP3A4 mAbs. An individual human liver microsomal sample HG6 and a pooled human liver microsomal sample HMM-0259 were used. The recombinant rCYPs (CYP2C9 or CYP3A4) were included to confirm the potency of respective antibody. A, treatment with anti-CYP2C9 mAb ascites. B, treatment with anti-CYP3A4 mAb ascites. C, treatment with anti-CYP2C9 and anti-CYP3A4 ascites.

Figure 5
Figure 5

Inhibition by anti-CYP2C9 and anti-CYP3A4 antibodies of celecoxib hydroxylase measured in human liver microsomal preparations of 16 subjects. The data are expressed as mean ± S.D. from three determinations.

Correlation Studies

The formation rates of hydroxy celecoxib were determined in 16 different human liver microsomal preparations. There was considerable interindividual variability in the values obtained with a mean ± S.D. activity (nanomoles per minute per milligram of protein) of 0.48 ± 0.17. As shown in Fig. 6, A and B, the rate of hydroxy celecoxib formation correlated with tolbutamide methyl-hydroxylation (CYP2C9) and testosterone 6β-hydroxylation (CYP3A4/5) activities (r = 0.92,P < .01 and r = 0.55,P < .05, respectively). Interestingly, the suppression of one of these CYPs by its corresponding antibody improved the correlation with the second CYP form. Namely, inhibition of celecoxib hydroxylation by antibody against CYP3A4 slightly improved the correlation with tolbutamide methyl-hydroxylase activity (r = 0.93, P < .005, Fig. 6C). However, inhibition of celecoxib hydroxylation by antibody against CYP2C9 significantly enhanced the correlation with testosterone 6β-hydroxylase activity (r = 0.96,P < .005, Fig. 6D). The correlation of hydroxy celecoxib formation with activities selective for other CYP isoforms [e.g., 7-ethoxyresorufin O-dealkylation, CYP1A2; coumarin 7-hydroxylation, CYP2A6; 7-ethoxy-4-trifluoro-methylcoumarin O-deethylation, CYP2B6; taxol-6-hydroxylation, CYP2C8; (S)-mephenytoin 4′-hydroxylation, CYP2C19; dextromethorphan-O-demethylation, CYP2D6; and chlorzoxazone 6-hydroxylation, CYP2E1] was not statistically significant (Table 2).

Figure 6
Figure 6

Correlation between hydroxy celecoxib formation and tolbutamide methyl-hydroxylase activity (A and C) and testosterone 6β-hydroxylase activity (B and D) in human liver microsomal samples (n = 16 subjects). A, hydroxy celecoxib formation in the absence of mAbs versus tolbutamide methyl-hydroxylase activity. B, hydroxy celecoxib formation in the absence of mAbs versus testosterone 6β-hydroxylase activity. C, hydroxy celecoxib formation in the presence of anti-CYP3A4 mAb versus tolbutamide methyl-hydroxylase activity. D, hydroxy celecoxib formation in the presence of anti-CYP2C9 versus testosterone 6β-hydroxylase activity.

View this table:
Table 2

Correlation of various CYP activities with the formation of hydroxy celecoxib in human liver microsomes

Chemical Inhibition

Based on the immunoinhibition and correlation data, three selective chemical inhibitors (SLF, KTZ, and QND) were chosen to substantiate the contribution of CYP2C9 and CYP3A4 in the metabolism of celecoxib. As displayed in Fig. 7, SLF (selective for CYP2C9) and KTZ (selective for CYP3A4) significantly inhibited the formation of hydroxy celecoxib in a concentration-dependent manner, whereas QND (selective for CYP2D6) did not show any significant effect (inhibition, <5%).

Figure 7
Figure 7

Effects of different concentrations of chemical inhibitors on human liver microsome-catalyzed celecoxib methyl hydroxylase activity (celecoxib was evaluated at a final concentration of 5 μM). Reaction rates are expressed as a percentage of the control velocity without inhibitor (mean ± S.D., n = 3 microsomal preparations).

Celecoxib Metabolism by cDNA-Expressed Human Cytochromes P450.

The CYP reaction phenotype of celecoxib was further evaluated with rCYP proteins. Consistent with the results obtained with native human liver microsomes, a decrease in celecoxib methyl hydroxylase activity was also observed when the substrate concentrations exceeded 15 μM (Fig.8A). Fitting the data acquired at substrate concentrations of ≤15 μM yielded an apparentKm value of 4.1 μM, which was comparable to that observed with native human liver microsomes. By comparison, the rCYP3A4-catalyzed metabolism of celecoxib was best described by a simple Michaelis-Menten equation and was characterized by a higher Km value (18 versus 4.1 μM) and a lower Vmax value (1.4 versus 17 pmol/min/pmol rCYP) compared with rCYP2C9 (Fig. 8B).

Figure 8
Figure 8

Rates of formation of hydroxy celecoxib by the recombinant CYP2C9 (A) and CYP3A4 (B). Insets, Eadie-Hofstee plots.

The rates of hydroxy celecoxib formation in the presence of several rCYPs are listed in Table 3. On normalization of the data with respect to the abundance of each enzyme in native human liver microsomes (Rodrigues, 1999), it was found that the majority (86%) of the hydroxylase activity was attributable to CYP2C9, although CYP3A (6%) did contribute. The normalized data were in agreement with the results of the immunoinhibition experiments.

View this table:
Table 3

Formation of hydroxy celecoxib by recombinant CYP proteins expressed in insect cells

Discussion

In the present study, it has been shown that the first step in the hepatic biotransformation of celecoxib (≤25 μM) involves a methyl hydroxylation reaction mediated principally by CYP2C9. The involvement of CYP2C9 is well supported by several lines of evidence: 1) a good correlation between the rate of hydroxy celecoxib formation and tolbutamide hydroxylase activity in a panel of human liver microsomes, 2) extensive inhibition of celecoxib metabolism by mAbs against CYP2C9 and SLF (a selective inhibitor of CYP2C9), and 3) a high turnover in the presence of human rCYP2C9. However, based on the results of this study, it is concluded that a member or members of the human liver microsomal CYP3A subfamily play a minor role (∼10%). For example, the correlation of celecoxib hydroxylase with testosterone 6β-hydroxylase was improved in the presence of anti-CYP2C9 (r = 0.96 versus 0.55). In addition, KTZ at 0.1 μM (a specific inhibitor of CYP3A) and anti-CYP3A4 mAbs significantly inhibited the formation of hydroxy celecoxib by 10%. The greater inhibitory effect seen at a higher concentration of KTZ (≥1 μM) may be attributable to the nonselective inhibition of CYP2C9 (Boobis, 1995).

The involvement of other CYP forms in the metabolism of celecoxib is unlikely. rCYP2D6 showed considerable activity (2.9 pmol/min/pmol rCYP2D6), but there was no correlation between celecoxib metabolism and dextromethorphan O-demethylase activity and no inhibition in the presence of QND (a selective inhibitor of CYP2D6) in native human liver microsomes. Similarly, although appreciable activity was observed with rCYP2C19 (3.2 pmol/min/pmol rCYP2C19), the poor correlation between celecoxib hydroxylase and (S)-mephenytoin 4′-hydroxylase in human liver microsomes did not support the involvement of the enzyme. However, it is possible that CYP2C19 may play a more prominent role in some individuals with higher CYP2C19 levels (Lasker et al., 1998). Moreover, metabolism by CYP2C8 in human liver microsomes was ruled out because of the weak correlation with taxol hydroxylase activity (Table 2). It should be noted that SLF would not be expected to inhibit (<10%) CYP2C8 and CYP2C19 at the concentrations used in the present study (Mancy et al., 1996).

The decrease in hydroxy celecoxib formation rate at higher substrate concentrations may be suggestive of substrate inhibition and the fact that simple Michaelis-Menten kinetics do not adequately model the kinetic data. In fact, the experimental data were best modeled by incorporation of a term for substrate inhibition. Unfortunately, the poor aqueous solubility of celecoxib prevented the use of high substrate concentrations, and it was not possible to better define the inhibition term. By comparison, other investigators have been able to use a wider range of substrate concentrations to successfully evaluate substrate inhibition (Goeger and Anderson, 1992; Gorski et al., 1994;Tucker et al., 1994; Schmider et al., 1996; von Moltke et al., 1996;Shiraga et al., 1999). Interestingly, substrate inhibition was limited to celecoxib hydroxylase activity catalyzed by CYP2C9 and was not observed with CYP3A4. Moreover, the phenomenon was observed with the recombinant enzyme and native liver microsomes. To our knowledge, celecoxib is the first CYP2C9 substrate that exhibits substrate inhibition; no similar findings have been reported for commonly used CYP2C9 probes, such as tolbutamide, diclofenac, and phenytoin.

Although CYP2C9 and CYP3A4 play a role in the metabolism of celecoxib, it is anticipated that celecoxib will not significantly interfere with the metabolism of other drugs catalyzed by CYP3A4. On the other hand, interaction with drugs metabolized by CYP2C9 is possible because of the relatively high affinity of celecoxib for the enzyme. Because CYP2C9 will largely govern celecoxib clearance at clinically relevant concentrations, the coadministration of other CYP2C9 inhibitors or inducers is likely to alter celecoxib clearance. For instance, fluconazole has been shown to increase the area under the curve of celecoxib (∼2-fold) (Celebrex package insert). Because fluconazole is a known CYP2C9 inhibitor (Kunze et al., 1996), these data attest to the role of the enzyme in the overall clearance of celecoxib. In addition, the pharmacokinetics of celecoxib will be dependent onCYP2C9 genotype, especially in subjects genotyped homozygous for the allelic variant forms (e.g., CYP2C9*2/*2 orCYP2C9*3/*3) of the enzyme (C. Tang, M. Shou, T. H. Rushmore, and A. D. Rodrigues, unpublished data; Miners and Birkett, 1998). It is important to note that CYP2C9 is one of the most abundant CYP enzymes in the human liver and has been shown to metabolize a large number of drugs, including tolbutamide, phenytoin, (S)-warfarin, losartan, sulfamethoxazole, and various NSAIDs (Goldstein and de Morais, 1994; Lasker et al., 1998; Miners and Birkett, 1998; Gill et al., 1999; McCrea et al., 1999). In summary, the results of the present study indicate that celecoxib methyl hydroxylation is largely catalyzed by CYP2C9, although CYP3A4 plays a minor role.

Footnotes

  • Send reprint requests to: Cuyue Tang, Ph.D., Department of Drug Metabolism, Merck Research Laboratories, Sumneytown Pike, P.O. Box 4, WP75A-203, West Point, PA 19486-0004. E-mail:cuyue-tang{at}merck.com

  • Abbreviations:
    COX
    cyclooxygenase
    rCYP
    recombinant CYP
    mAb
    monoclonal antibody
    SLF
    sulfaphenazole
    KTZ
    ketoconazole
    QND
    quinidine
    LC
    liquid chromatography
    MS
    mass spectometry
    Km
    apparent Michaelis constant
    Vmax
    maximal initial reaction velocity
    NSAID
    nonsteroidal anti-inflammatory drug
    • Received October 21, 1999.
    • Accepted January 17, 2000.

References

  1. ↵
    1. Battistini B,
    2. Botting R,
    3. Bakhle YS
    (1994) COX-1 and COX-2: Toward the development of more selective NSAIDs. Drug News Perspect 7:501–512.
    OpenUrl
  2. ↵
    1. Pacifici GM,
    2. Fracchia GN
    1. Boobis AR
    (1995) Prediction of inhibitory drug-drug interactions by studies in vitro. in Advances in Drug Metabolism in Man, eds Pacifici GM, Fracchia GN pp 515–539, , Luxembourg, Brussels..
  3. ↵
    1. Bourrie M,
    2. Meunier V,
    3. Berger Y,
    4. Fabre G
    (1995) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321–332.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Donnelly MT,
    2. Hawkey CJ
    (1997) COX-II inhibitors: A new generation of safer NSAIDs? Aliment Pharmacol Ther 11:227–236.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Gill HJ,
    2. Tjia JF,
    3. Kitteringham NR,
    4. Pirmohamed M,
    5. Back DJ,
    6. Park BK
    (1999) The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. Pharmacogenetics 9:43–53.
    OpenUrlPubMed
  6. ↵
    1. Goeger DE,
    2. Anderson KE
    (1992) Biochemical characterization of coumarin 7-hydroxylase activity in chick embryo liver microsomes. Biochem Pharmacol 43:363–369.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Goldstein JA,
    2. de Morais SMF
    (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285–299.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Gorski JC,
    2. Hall SD,
    3. Jones DR,
    4. VandenBranden M,
    5. Wrighton R
    (1994) Regioselective biotransformation of midazolam by members of the human CYP3A subfamily. Biochem Pharmacol 47:1643–1653.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Graul A,
    2. Martel AM,
    3. Castan̆er
    (1997) Celecoxib: Antiinflammatory cyclooxygenase-2 inhibitor. Drugs Future 22:711–714.
    OpenUrl
  10. ↵
    1. Jouzeau JY,
    2. Terlain B,
    3. Abid A,
    4. Nedelec E,
    5. Netter P
    (1997) Cyclooxygenase isoenzymes: How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 53:563–582.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Karim A,
    2. Tolbert D,
    3. Burton E,
    4. Piergies A,
    5. Harper K,
    6. Paulson S,
    7. Schoenhard G,
    8. Hubbard R,
    9. Isakson P,
    10. Geis S
    (1997) A highly selective inhibitor of cyclooxygenase-2: Disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation. Pharm Res 14:S617.
    OpenUrl
  12. ↵
    1. Kunze KL,
    2. Wienkers LC,
    3. Thummel KE,
    4. Trager WF
    (1996) Warfarin-fluconazole I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies. Drug Metab Dispos 24:414–421.
    OpenUrlAbstract
  13. ↵
    1. Lane NE
    (1997) Pain management in osteoarthritis: The role of COX-2 inhibitors. J Rheumatol 24:20–24.
  14. ↵
    1. Lasker JM,
    2. Wester MR,
    3. Aramsombatdee E,
    4. Raucy JL
    (1998) Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353:16–28.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Leatherbarrow RJ
    (1992) GraFit Version 3.0. (Erithacus Software Ltd. Staines, UK).
  16. ↵
    1. Lipsky PE,
    2. Isakson PC
    (1997) Outcome of specific COX-2 inhibition on rheumatoid arthritis. J Rheumatol 24 (Suppl 49) 9–14.
  17. ↵
    1. Mancy A,
    2. Dijols S,
    3. Poli S,
    4. Guengerich FP,
    5. Mansuy D
    (1996) Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9. Biochemistry 35:16205–16212.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Mei Q,
    2. Tang C,
    3. Assang C,
    4. Slaughter D,
    5. Rodrigues AD,
    6. Rushmore TH,
    7. Shou M
    (1999) Role of a potent inhibitory monoclonal antibody to cytochrome P450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291:749–759.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. McCrea JB,
    2. Cribb A,
    3. Rushmore T,
    4. Osborne B,
    5. Gillen L,
    6. Lo MW,
    7. Waldman S,
    8. Bjornsson T,
    9. Spielberg S,
    10. Goldberg MR
    (1999) Phenotype and genotype investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin Pharmacol Ther 65:348–352.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Miners JO,
    2. Birkett DJ
    (1998) Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525–538.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Newton DJ,
    2. Wang RW,
    3. Lu AYH
    (1995) Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154–158.
    OpenUrlAbstract
    1. Noda K,
    2. Suzuki A,
    3. Okui M,
    4. Noguchi H,
    5. Nishiura M,
    6. Nishiura N
    (1979) Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylaminoethoxy)-dibenzo [b, f]thiepine (zotepine) in rat, mouse, dog and man. Arzneim-Forsch 29:1595–1600.
    OpenUrlPubMed
  23. ↵
    1. O'Neill GP,
    2. Mancini JA,
    3. Kargman S,
    4. Yergey J,
    5. Kwan MY,
    6. Falgueyret JP,
    7. Abramovitz M,
    8. Kennedy BP,
    9. Ouellet M,
    10. Cromlish W,
    11. Culp S,
    12. Evans JF,
    13. Ford-Hutchinson AW,
    14. Vickers PJ
    (1994) Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: Inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol 45:245–254.
    OpenUrlAbstract
  24. ↵
    1. Penning TD,
    2. Talley JJ,
    3. Bertenshaw SR,
    4. Carter JS,
    5. Collins PW,
    6. Docter S,
    7. Graneto MJ,
    8. Lee LF,
    9. Malecha JW,
    10. Miyashiro JM,
    11. Rogers RS,
    12. Rogier DJ,
    13. Yu SS,
    14. Anderson GD,
    15. Burton EG,
    16. Cogburn JN,
    17. Gregory SA,
    18. Koboldt CM,
    19. Perkins WE,
    20. Seibert K,
    21. Veenhuizen AW,
    22. Zhang YY,
    23. Isakson PC
    (1997) Synthesis and biological evaluation of the 1,5-diarypyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluromethyl)-1H-pyrazol-1-yl]benzensulfonamide (SC-58635, Celecoxib). J Med Chem 40:1347–1365.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Riendeau D,
    2. Charleson S,
    3. Cromlish W,
    4. Mancini JA,
    5. Wong E,
    6. Guay J
    (1997) Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drug (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmacol 75:1088–1095.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Rodrigues AD
    (1999) Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465–480.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Rodrigues AD,
    2. Kukulka MJ,
    3. Roberts EM,
    4. Ouellet D,
    5. Rodgers TR
    (1996) [O-methyl 14C]Naproxen O-demethylase activity in human liver microsomes: Evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab Dispos 24:126–136.
    OpenUrlAbstract
  28. ↵
    1. Schmider J,
    2. Greenblatt DJ,
    3. Harmatz JS,
    4. Shader RI
    (1996) Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: Application to amitriptyline N-demethylation. Br J Clin Pharmacol 41:593–604.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Shiraga T,
    2. Kaneko H,
    3. Iwasaki K,
    4. Tozuka Z,
    5. Suzuki A,
    6. Hata T
    (1999) Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica 29:217–229.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Simon LS,
    2. Lanza FL,
    3. Lipsky PE,
    4. Hubbard RC,
    5. Talwalker S,
    6. Schwartz BD,
    7. Isakson PC,
    8. Geis GS
    (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthitis and rheumatiod arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41:1591–1602.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Smith WL,
    2. DeWitt DL
    (1996) Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 62:167–215.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Tucker GT,
    2. Lennard MS,
    3. Ellis SW,
    4. Woods HF,
    5. Cho AK,
    6. Lin Ly,
    7. Hiratsuka A,
    8. Schmitz DA,
    9. Chu TY
    (1994) The demethylation of methylenedioxymethamphetamine (“ecstasy”) by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151–1156.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Vane JR,
    2. Bakhle YS,
    3. Botting RM
    (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97–120.
    OpenUrlCrossRefPubMed
  34. ↵
    1. von Moltke LL,
    2. Greenblatt DJ,
    3. Schmider J,
    4. Duan SX,
    5. Wright CE,
    6. Harmatz JS,
    7. Shader RI
    (1996) Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36:783–791.
    OpenUrlPubMed
View Abstract
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY

Major Role of Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) in the Oxidative Metabolism of Celecoxib, a Novel Cyclooxygenase-II Inhibitor

Cuyue Tang, Magang Shou, Qin Mei, Thomas H. Rushmore and A. David Rodrigues
Journal of Pharmacology and Experimental Therapeutics May 1, 2000, 293 (2) 453-459;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section